BRAF and melanoma: Although the implications of BRAF mutations in the pathogenesis of solid cancers (especially melanoma) are well established and BRAF inhibitors are already in clinical use for patients with melanoma and other malignancies, the role of BRAF in hematological malignancies is still underexplored [16,17,18].